<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750893</url>
  </required_header>
  <id_info>
    <org_study_id>111700</org_study_id>
    <nct_id>NCT00750893</nct_id>
  </id_info>
  <brief_title>Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants</brief_title>
  <official_title>Safety of GlaxoSmithKline Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ or Rotarix™ Liquid Formulation (Oral Suspension or Prefilled Syringe) When Administered According to the Prescribing Information in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This protocol posting deals with objectives and outcome measures of the primary phase at one
      month post-Dose 2. This Post Marketing Surveillance (PMS) will collect safety data on the use
      of human rotavirus vaccine in at least 3000 evaluable infants in Korea. This study involves
      male or female infants from the age of 6 weeks at the time of the first vaccination. The
      vaccination course must be completed by the age of 24 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol posting has been amended to reflect the two new vaccine presentations that have
      been launched in Korea. The current PMS will thus collect safety information from subjects
      who have received either Rotarix™ or Rotarix™ liquid formulation (oral suspension or
      prefilled syringe) in the course of their routine clinical practice according to the
      prescribing information in Korea.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms</measure>
    <time_frame>During the 8 day follow-up period after each vaccine dose for Year 1 &amp; Year 2 study period</time_frame>
    <description>Solicited general symptoms assessed include cough, diarrhoea, irritability, loss of appetite, temperature and vomiting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 31 day follow-up period after each vaccine dose for Year 1 &amp; Year 2 study period</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 31 day follow-up period after each vaccine dose for Year 3 &amp; Year 4 study period</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 31 day follow-up period after each vaccine dose for Year 5 study period</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 31 day follow-up period after each vaccine dose for Year 1 to Year 6 study period</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>During the post marketing study period for Year 1 &amp; Year 2 study period</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>During the post marketing study period for Year 3 &amp; Year 4 study period</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>During the post marketing study period for Year 5 study period</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>During the post marketing study period for Year 1 to Year 6 study period</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3111</enrollment>
  <condition>Infections, Rotavirus</condition>
  <arm_group>
    <arm_group_label>Rotarix Group</arm_group_label>
    <description>Subjects who received 2 doses of Rotarix™ or Rotarix™ liquid formulation (oral suspension or prefilled syringe ). The first dose was administered from the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix™ or Rotarix™ liquid formulation (oral suspension or prefilled syringe)</intervention_name>
    <description>GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine.</description>
    <arm_group_label>Rotarix Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infants aged at least 6 weeks will be administered two doses of Rotarix™ or Rotarix™ liquid
        formulation (oral suspension or prefilled syringe) orally as per the prescribing
        information in Korea.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants who the investigator believes that their parents/guardians can and will comply
             with the requirements of the protocol should be enrolled in the PMS.

          -  A male or female infant from the age of 6 weeks at the time of the first vaccination.

          -  Written informed consent obtained from the parent or guardian of the infant.

        Exclusion Criteria:

        • At the time of PMS entry, the contraindications and precautions of use indicated in the
        prescribing information should be checked and the infant must not be included in the PMS if
        there is any contraindication. Any changes in the locally approved Prescribing Information
        must be implemented immediately.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>24 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>122-896</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2008</study_first_submitted>
  <study_first_submitted_qc>September 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2008</study_first_posted>
  <results_first_submitted>January 28, 2011</results_first_submitted>
  <results_first_submitted_qc>January 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2011</results_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroenteritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This post marketing study (PMS) will cover a period of 6 consecutive years. Results are presented for Years 1, 2, 3, 4, 5 (Year [Y] 1 &amp; Y2 data combined and presented at the Y2 time point and Y3 &amp; Y4 data combined and presented at the Y4 time point) along with consolidated surveillance data from Y1- Y6 timepoint.</recruitment_details>
      <pre_assignment_details>Consolidated participant flow and baseline measure data are given for Years 1 to 6 time point in order to account for all the subjects participating in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rotarix Group</title>
          <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2569"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="542"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="510"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rotarix Group</title>
          <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include cough, diarrhoea, irritability, loss of appetite, temperature and vomiting.</description>
        <time_frame>During the 8 day follow-up period after each vaccine dose for Year 1 &amp; Year 2 study period</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include cough, diarrhoea, irritability, loss of appetite, temperature and vomiting.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="876"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the 31 day follow-up period after each vaccine dose for Year 1 &amp; Year 2 study period</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="876"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the 31 day follow-up period after each vaccine dose for Year 3 &amp; Year 4 study period</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1052"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the 31 day follow-up period after each vaccine dose for Year 5 study period</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="708"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the 31 day follow-up period after each vaccine dose for Year 1 to Year 6 study period</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the post marketing study period for Year 1 &amp; Year 2 study period</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="876"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the post marketing study period for Year 3 &amp; Year 4 study period</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1052"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the post marketing study period for Year 5 study period</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="708"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the post marketing study period for Year 1 to Year 6 study period</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects with at least one dose of Rotarix™ vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events: during Years 1, 2, 3, 4, 5 and 6 post market study period. Systematically and non-systematically assessed frequent adverse events: during the 8 day and 31 day follow-up period after each vaccine dose respectively.</time_frame>
      <desc>Classification for AEs was performed differently across the study period, according to MedDRA preferred terms until Year 4, and to World Health Organisation’s Adverse Reactions Terminology (WHO ART) Dictionary for Year 5 and for the consolidated results from Year 1 to Year 6.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rotarix Years 1 and 2 Group</title>
          <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age. This group contains the subjects enrolled during Years 1 and 2 of the study.</description>
        </group>
        <group group_id="E2">
          <title>Rotarix Years 3 and 4 Group</title>
          <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age. This group contains the subjects enrolled during Years 3 and 4 of the study.</description>
        </group>
        <group group_id="E3">
          <title>Rotarix Year 5 Group</title>
          <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age. This group contains the subjects enrolled during Year 5 of the study.</description>
        </group>
        <group group_id="E4">
          <title>Rotarix Year 1 to Year 6 Group</title>
          <description>Subjects who received 2 oral doses of Rotarix™. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age. This group contains the subjects enrolled during the study period from Year 1 to Year 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title vocab="WHO ART">Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title vocab="WHO ART">Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="WHO ART">Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title vocab="WHO ART">Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="WHO ART">Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title vocab="WHO ART">Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title vocab="WHO ART">Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title vocab="WHO ART">Croup</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title vocab="WHO ART">Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title vocab="WHO ART">Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="405" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="269" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="405" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Temperature</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="269" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="WHO ART">Bronchiolitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="159" subjects_at_risk="3111"/>
              </event>
              <event>
                <sub_title vocab="WHO ART">Common cold</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="876"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="129" subjects_at_risk="3111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

